KLE Xenograft Model Service for Endometrial Cancer

KLE Xenograft Model Service for Endometrial Cancer provides a robust preclinical platform for evaluating therapeutic candidates against a poorly differentiated, hormone-refractory type II endometrial carcinoma phenotype. Alfa Cytology leverages validated KLE cell stocks, stringent quality control, and standardized xenograft protocols to deliver reproducible tumor data that accelerates your endometrial cancer drug development pipeline.

Overview of KLE Xenograft Model for Endometrial Cancer

The KLE xenograft model is established from the KLE human endometrial carcinoma cell line, originally derived in 1982 from a poorly differentiated endometrioid adenocarcinoma of a 64-year-old patient. KLE cells are classified as a type II endometrial cancer model, exhibiting aneuploid karyotypes (51-66 chromosomes), defective estrogen receptor-alpha (ERalpha) signaling with absent nuclear translocation, and lack of PTEN mutations, making them representative of aggressive, hormone-independent endometrial carcinoma. In vivo, KLE cells demonstrate potent tumorigenicity, forming subcutaneous tumors in nude mice with 100% frequency within 21 days at standard inoculum doses. Tumor histology recapitulates the original poorly differentiated morphology, displaying microvilli, junctional complexes, and nucleolar channel systems akin to progestational endometrium, yet without glandular formation. This model is extensively utilized in orthotopic and subcutaneous settings to assess epigenetic inhibitors, hormonal agents, chemotherapeutics, and targeted compounds.

Key research applications of the KLE xenograft include evaluation of LSD1 inhibitors, ERRalpha inverse agonists, combination regimens with cisplatin and TRAIL, and studies on progestin resistance. Its ERalpha-negative, progesterone receptor-positive (PR+) profile and high ERRalpha expression render KLE particularly valuable for testing therapies aimed at hormone-refractory endometrial cancer and for investigating mitochondrial and epigenetic drivers of tumor progression.

Figure 1. The growth-inhibitory effect of hinokitiol on endometrial cancer cells. (Chen, Hsin-Yuan, et al., 2021)

Cell Line Information: KLE

The KLE cell line is a well-characterized human endometrial adenocarcinoma line with distinct molecular and phenotypic features that define its utility in preclinical oncology research. Detailed characteristics are summarized below.

Our Services

Alfa Cytology provides end-to-end KLE xenograft model services tailored to your preclinical program, from cell line authentication and immunodeficient mouse procurement to tumor monitoring, endpoint analysis, and comprehensive histopathological reporting. Our experienced team ensures that every study is executed under rigorous quality standards, delivering reliable data to support your IND-enabling and publication objectives in endometrial cancer research.

Workflow of KLE Xenograft Model Construction

Alfa Cytology follows a standardized, GLP-compliant workflow to construct KLE xenograft models, ensuring reproducible tumor growth and reliable pharmacodynamic readouts. The process is summarized below in sequential steps.

1. Cell Line Authentication & Expansion: KLE cells are revived from authenticated master stocks (ATCC CRL-1622) and verified by STR profiling prior to expansion. Cells are cultured under standardized conditions (DMEM/F12, 10% FBS) and harvested at logarithmic growth phase for optimal viability.
2. Mouse Strain Selection & Preparation: Immunodeficient nude mice (e.g., BALB/c nude or NOD-SCID) are acclimatized and health-screened. Mouse age, weight, and sex are matched across groups to minimize inter-animal variability.
3. Cell Inoculation & Tumor Induction: KLE cells are prepared as a cell suspension in serum-free medium mixed with Matrigel (typically 1:1) to enhance engraftment. A defined cell number (e.g., 1 x 10^7 cells per site) is injected subcutaneously into the flank or orthotopically into the uterine horn, depending on study design.
4. Tumor Monitoring & Randomization: Tumors are measured by caliper twice weekly. Upon reaching a palpable volume (typically 50-100 mm^3), animals are randomized into treatment and control cohorts to ensure balanced baseline tumor volumes across groups.
5. Treatment Administration & In-Life Observations: Test articles are administered via the specified route (oral gavage, intraperitoneal, or intravenous) according to the study protocol. Body weight, tumor dimensions, and clinical signs are recorded throughout the in-life phase.
6. Endpoint Analysis & Tissue Collection: At study termination, tumors are excised, weighed, and photographed. Tumor growth inhibition (TGI) is calculated. Tissues are fixed for histopathology (H&E, IHC), snap-frozen for molecular analysis, or processed for flow cytometry as required.
7. Data Compilation & Reporting: All data are compiled into a comprehensive study report including tumor growth curves, TGI statistics, body weight trends, and representative histopathology images, delivered in a format ready for regulatory or publication use.

Figure 2: Schematic workflow illustrating the derivation and construction of the KLE Xenograft Model at Alfa Cytology.

Case Study-KLE Xenograft Model Development

In a representative preclinical engagement, KLE cells were expanded under strict authentication protocols and inoculated subcutaneously into immunodeficient mice to establish a type II endometrial carcinoma xenograft. Tumors reached evaluable volume within 14-21 days with consistent take rates. Treatment cohorts received a candidate therapeutic agent or vehicle control, with tumor dimensions and body weights monitored throughout the study. Preliminary data indicated dose-dependent tumor growth inhibition, with treated groups showing statistically significant reductions in tumor volume compared to vehicle controls. Comprehensive histopathological and biomarker analyses were performed to elucidate mechanism of action. Full datasets, including pharmacokinetic-pharmacodynamic correlations and survival outcomes, are available upon request and can be customized to align with your specific program requirements.

Why Choose Alfa Cytology?

Alfa Cytology is a specialized preclinical CRO committed to delivering high-fidelity tumor models and actionable data for oncology drug development. Our KLE xenograft service is distinguished by the following advantages:

• Authenticated KLE cell stocks with verified STR profiles and documented passage history to ensure genetic fidelity across studies.
• Standardized xenograft protocols optimized for KLE tumorigenicity, yielding rapid engraftment and consistent tumor growth kinetics.
• Flexible study designs accommodating subcutaneous, orthotopic, and patient-derived xenograft (PDX) combination approaches.
• Comprehensive endpoint capabilities including tumor growth inhibition analysis, histopathology, immunohistochemistry, and biomarker quantification.
• Dedicated project management with transparent timelines, real-time data access, and customized reporting formats for IND and publication needs.
• Competitive pricing and rapid study initiation to accelerate your endometrial cancer preclinical pipeline without compromising quality.

Contact Us

Ready to advance your endometrial cancer therapeutic program with a validated KLE xenograft model? Contact us today to discuss your study objectives, timeline, and custom endpoint requirements. Reach out to our scientific team to receive a tailored proposal and learn how Alfa Cytology can accelerate your preclinical research from concept to data delivery.

For research use only. Not intended for any clinical use.